Aldeyra Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALDX Nasdaq 8731 https://www.aldeyra.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aldeyra Therapeutics Inc

Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why - Apr 6th, 2024 10:37 am
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? - Apr 5th, 2024 1:40 pm
Health Care Roundup: Market Talk - Apr 4th, 2024 4:36 pm
Aldeyra's Dry Eye Disease Drug May Be on Path for FDA Approval - Apr 3rd, 2024 6:58 pm
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The Corner - Apr 3rd, 2024 11:17 am
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease - Mar 28th, 2024 11:00 am
Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares - Mar 13th, 2024 6:33 am
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now - Mar 6th, 2024 2:40 pm
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? - Mar 4th, 2024 2:40 pm
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics - Mar 1st, 2024 2:45 pm
5 Small Drug Stocks to Buy From a Rebounding Industry - Feb 29th, 2024 1:53 pm
Institutions own 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares but retail investors control 37% of the company - Feb 22nd, 2024 12:35 pm
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference - Feb 6th, 2024 12:00 pm
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases - Jan 4th, 2024 12:00 pm
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis - Dec 19th, 2023 12:00 pm
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis - Dec 18th, 2023 9:01 pm
13 Hot Penny Stocks To Buy According to Hedge Funds - Dec 6th, 2023 4:55 pm
Semtech (SMTC) to Release Q3 Earnings: What's in the Cards? - Dec 5th, 2023 6:59 pm
Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings? - Dec 5th, 2023 2:00 pm
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease - Nov 27th, 2023 9:07 pm